About Clinical Trials for DM199
DiaMedica’s investigational drug product candidate, DM199 (rhKLK1), is a recombinant form of the human tissue kallikrein-1 protein (KLK1) and is being evaluated in clinical studies to treat ischemic diseases.
DM199 for Pregnancy Complications
[Currently Enrolling]
DM199 for Pregnancy Complications is currently in a Phase 2 investigator-sponsored trial assessing DM199 (rhKLK1) as a potential therapy for preeclampsia and fetal growth restriction – conditions with no FDA-approved therapies.
DM199 for Acute Ischemic Stroke (ReMEDy2)
[Currently Enrolling]
ReMEDy2 is a Phase 2/3 study investigating DM199 (rhKLK1) as a novel acute ischemic stroke treatment intended to safely improve stroke recoveries in a patient population with no treatment options.
Enrollment
For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
The safety and effectiveness of DM199 for the treatment of acute ischemic stroke or preeclampsia has not been established and is limited to investigational use only.